To include your compound in the COVID-19 Resource Center, submit it here.

ALLP deal continues revival for blood product

After a prolonged dearth of favorable news about blood substitutes, corporate persistence is building toward the next threshold of product development events.

Last week's announcement by Alliance Pharmaceutical Corp. that it signed an exclusive licensing agreement with Johnson & Johnson's Ortho Biotech Inc. makes it the second blood substitute company this year to partner with a pharmaceutical company that will take on the substantial costs of late-stage development of the

Read the full 710 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers